Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2

Clin Pharmacol Ther. 2020 Aug;108(2):188. doi: 10.1002/cpt.1877. Epub 2020 May 21.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Amides
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections*
  • Humans
  • Pandemics*
  • Pneumonia, Viral*
  • Pyrazines
  • SARS-CoV-2
  • Severe acute respiratory syndrome-related coronavirus*

Substances

  • Amides
  • Pyrazines
  • favipiravir